NSCLC for Phase 2 Dose Expansion
1 clinical trials · Condition
◉ Watch NSCLC for Phase 2 Dose Expansion
| Record | Firm | Date |
|---|---|---|
| Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors (NCT03744468) | BeiGene | 2018-11-13 |
Track NSCLC for Phase 2 Dose Expansion automatically
Every clearance here is in the API, with alerts when new ones post.